Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels

Change From Baseline in LDL-C at Week 12

LDL-C was measured using ultracentrifugation.

Time frame: Baseline and Week 12

Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12

Time frame: Baseline and Week 12

Percent Change From Baseline in Apolipoprotein B at Week 12

Time frame: Baseline and Week 12

Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12

Time frame: Baseline and Week 12

Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 Ratio at Week 12

Time frame: Baseline and Week 12